Mazdutide: Research & Evidence
Established EvidencePublished research, clinical trial data, and evidence grading for Mazdutide across studied indications.
Back to Mazdutide overviewResearch Summary
Mazdutide has approximately 5-10 completed RCTs, primarily in Chinese populations. The Phase 3 GLORY-2 trial demonstrated up to 20.1% weight loss at 9 mg in adults with obesity. The Phase 3 DREAMS-3 head-to-head trial showed superiority over semaglutide in both glycemic control and weight loss. NMPA (China) approved mazdutide in September 2025 for Type 2 Diabetes glycemic control — making it the world's first approved GCG/GLP-1 dual agonist. However, mazdutide is NOT FDA approved and has no active US IND as of March 2026. All clinical data comes from Chinese populations; efficacy in other ethnic groups is not established.
Evidence by Indication (2 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Type 2 Diabetes (glycemic control) | Tier A | 5 | Multiple Phase 2/3 RCTs; NMPA approved September 2025 |
| Obesity / weight management | Tier B | 3 | Phase 3 GLORY-2 showed 20.1% weight loss; not yet approved for this indication |
Graded using our evidence tier methodology.
Citations (4 sources)
- 1. Efficacy and safety of mazdutide in Chinese adults with obesity: the Phase 3 GLORY-2 trial Clinical Trial
Innovent Biologics investigators (2025), The Lancet
- 2. Mazdutide versus semaglutide in Chinese adults with Type 2 Diabetes: the Phase 3 DREAMS-3 head-to-head trial Clinical Trial
Innovent Biologics investigators (2025), Diabetes Care
- 3. Safety and efficacy of mazdutide in Chinese overweight adults or adults with obesity: a randomised, double-blind, placebo-controlled phase 2 trial Clinical Trial
Innovent Biologics investigators (2023), The Lancet Diabetes & Endocrinology
- 4. Mazdutide in Type 2 Diabetes: a Phase 2 randomized, double-blind, placebo-controlled trial Clinical Trial
Innovent Biologics investigators (2024), Diabetes Care